Phase 1 Safety and Immunogenicity Evaluation of ADVAX a Multigenic DNA-Based Clade C/B HIV-1 Candidate Vaccine

摘要

BackgroundWe conducted a Phase I dose escalation trial of ADVAX, a DNA-based candidate HIV-1 vaccine expressing Clade C/B' env, gag, pol, nef, and tat genes. Sequences were derived from a prevalent circulating recombinant form in Yunnan, China, an area of high HIV-1 incidence. The objective was to evaluate the safety and immunogenicity of ADVAX in human volunteers.